GOVX Stock Balance Sheets

GeoVax Labs Quarterly Balance Sheets Chart

Quarterly

Annual

Account Receivables

Cash and Cash Eq

Account Payables

GeoVax Labs Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2015-12-31	2014-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31

assets
current assets:
cash and cash equivalents	1,561,712	768,859	6,452,589	12,687,041	17,788,911	23,849,860	27,612,732	34,676,968	30,902,454	16,257,716	11,423,870	18,107,019	19,538,513	20,842,782	221,807	11,580,594	710,682	283,341	569,359	216,411	175,985	259,701	511,242	190,969	571,154	312,727	1,060,348	1,101,651	1,035,925	1,167,980	1,079,087	3,515,784	2,191,180	1,990,356
accounts receivable	300,677
prepaid expenses	1,981,134	2,093,519	1,433,153	2,113,249	2,038,283	2,138,971	1,325,998	1,460,207	1,135,780
total current assets	3,843,523	2,862,378	7,885,742	14,800,290	19,827,194	25,988,831	28,938,730	36,137,175	32,038,234	16,636,890	11,629,116	18,159,837	19,656,551	20,961,212	810,211	11,734,794	938,315	447,264	795,590	319,796	447,909	619,704	596,187	339,149	802,324	448,074	1,236,975	1,225,495	1,344,474	1,418,003	1,602,192	3,880,720	2,801,834	3,030,814
property and equipment	170,537	190,113	209,689	212,953	224,080	217,593	234,912	248,983	214,783	206,855	156,938	168,653	149,799	143,224	9,612	10,093	8,618	10,606	9,929	11,827	13,725	11,350	16,270	21,221	26,171	31,151	83,608	96,693
other assets	81,010	305,691	1,187,788	1,187,788	1,197,788	1,197,788	2,174,286	2,184,286	987,508																		11,010	11,010
total assets	4,095,070	3,358,182	9,283,219	16,201,031	21,249,062	27,404,212	31,347,928	38,570,444	33,240,525	16,854,755	11,797,064	18,339,500	19,817,360	21,115,446	830,833	11,755,897	957,943	468,880	816,529	342,633	472,644	642,064	623,467	371,380	839,505	490,235	1,331,593	1,333,198	1,477,970	1,645,142	2,357,834	4,315,597	3,056,241	3,246,404
liabilities and stockholders’ equity
current liabilities:
accounts payable	3,983,696	1,883,844	2,802,950	4,213,295	871,131	1,287,995	1,747,682	1,079,421	237,315	426,103	2,057,534	289,438	289,680	232,482	740,829	161,478	91,416	152,653	63,143	116,207	253,166	125,859	147,947	66,032	54,039	77,581	100,935	55,616	163,788	138,339
notes payable and accrued interest – related parties	142,292
accrued expenses	2,278,308	1,420,063	716,931	2,868,390	3,214,381	3,251,060	3,000,212	3,709,984	3,130,553	3,075,000	3,377,826	46,212	69,342	36,623	1,917,425	579,585	2,076,359	1,851,040	1,732,438	1,510,268	1,378,710	1,238,552	1,149,758	998,062	864,358	733,711	4,055	52,490	33,877	125,869
total current liabilities	6,404,296	3,303,907	3,519,881	7,081,685	4,085,512	4,539,055	4,747,894	4,789,405	3,367,868	3,501,103	5,435,360	335,650	359,022	451,949	2,670,302	923,647	2,785,865	2,016,193	1,808,081	1,638,975	1,644,376	1,624,831	1,304,999	1,068,262	919,439	811,292	126,990	187,023	327,035	941,535	521,608	571,365	346,422	598,538
commitments
stockholders’ equity
common stock							26,335				6,382							300											18,733	16,443	15,655	781,628	747,449	731,628
authorized shares – 150,000,000 and 600,000,000 at june 30, 2024 and december 31, 2023, respectively
issued and outstanding shares – 4,178,700 and 1,977,152 at june 30, 2024 and december 31, 2023, respectively	4,179
additional paid-in capital	112,964,554	110,265,884	110,125,146	105,864,028	105,499,665	105,273,652	104,970,722	104,767,918	96,901,530	78,147,616	68,731,220	68,630,363	68,134,402	67,937,289	41,189,070	55,203,149	41,658,861	39,340,224	38,818,750	38,165,172	37,898,525	37,264,301	36,830,813	36,558,210	36,219,889	35,589,911	32,587,543	30,823,769	25,587,148	23,319,166	22,105,747	20,500,452	16,215,966	12,441,647
accumulated deficit	-115,277,959	-110,213,917	-104,363,785	-96,771,377	-88,362,559	-82,434,939	-78,397,023	-73,013,214	-69,045,112	-66,803,413	-64,375,898	-50,632,895	-48,682,392	-47,368,359	-43,443,207	-44,469,059	-43,898,411	-42,847,513	-42,256,920	-41,832,486	-41,178,338	-40,476,884	-39,842,539	-39,175,646	-38,538,603	-37,916,790	-32,474,927	-29,785,640
total stockholders’ equity	-2,309,226	54,275	5,763,338	9,119,346	17,163,550	22,865,157	26,600,034	31,781,039	27,872,657	11,353,652	4,361,704	18,003,850	19,458,338	20,651,340	-1,864,250	10,813,744	-1,849,621	-1,574,556	-1,020,719	-1,328,633	-1,207,149	-1,022,347	-724,238	-742,714	-128,892	-321,057	1,204,603	1,146,175	1,150,935	703,607	1,836,226	3,744,232	2,709,819	2,647,866
total liabilities and stockholders’ equity	4,095,070	3,358,182	9,283,219	16,201,031	21,249,062	27,404,212	31,347,928	38,570,444	33,240,525	16,854,755	11,797,064	18,339,500	19,817,360	21,115,446	830,833	11,755,897	957,943	468,880	816,529	342,633	472,644	642,064	623,467	371,380	839,505	490,235	1,331,593	1,333,198	1,477,970	1,645,142	2,357,834	4,315,597	3,056,241	3,246,404
stockholders’ equity:
authorized shares – 150,000,000 and 600,000,000 at march 31, 2024 and december 31, 2023, respectively
issued and outstanding shares – 2,308,309 and 1,977,152 at march 31, 2024 and december 31, 2023, respectively		2,308
authorized shares – 600,000,000
issued and outstanding shares – 1,977,152 and 1,755,664 at december 31, 2023 and 2022, respectively			1,977
issued and outstanding shares – 26,695,287 and 26,334,953 at september 30, 2023 and december 31, 2022, respectively				26,695
issued and outstanding shares – 26,443,649 and 26,334,953 at june 30, 2023 and december 31, 2022, respectively					26,444
authorized shares – 600,000,000 issued and outstanding shares – 26,443,649 and 26,334,953 at march 31, 2023 and december 31, 2022, respectively						26,444
grant funds receivable																										59,758	119,978	79,341	266,248	183,515	474,275	320,321	311,368	93,260
other liabilities								2,000,000	2,000,000
total liabilities							4,747,894	6,789,405	5,367,868	5,501,103	7,435,360	335,650	359,022	464,106	2,695,083	942,153	2,807,564	2,043,436	1,837,248	1,671,266	1,679,793	1,664,411	1,347,705	1,114,094	968,397
authorized shares – 600,000,000 issued and outstanding shares – 26,334,953 and 6,381,541 at september 30, 2022 and december 31, 2021, respectively								26,335
authorized shares – 600,000,000 issued and outstanding shares – 16,238,739 and 6,381,541 at june 30, 2022 and december 31, 2021, respectively									16,239
grant funds and other receivables										99,526	49,006				520,509	141,154	187,163	68,603	103,485	64,246	160,277	121,814	14,757		5,000
prepaid expenses and other current assets										279,648	156,240	52,818	118,038	118,430	67,895	13,046	40,470	95,320	122,746	39,139	111,647	238,189	70,188	148,180	226,170	75,589	56,649	44,503	42,301	66,508
deposits										11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010	11,010							980	980
accrued expenses - noncurrent										2,000,000
authorized shares – 600,000,000 issued and outstanding shares – 9,449,025 and 6,381,541 at march 31, 2022 and december 31, 2021, respectively										9,449
current portion of notes payable														182,844	12,048	182,584	182,379	12,500	12,500	12,500	12,500	260,420
accrued expenses – noncurrent											2,000,000
note payable, net of current portion														12,157	24,781	18,506	21,699	27,243	29,167	32,291	35,417	39,580	42,706	45,832	48,958
preferred stock, .01 par value: authorized shares – 10,000,000 series b convertible preferred stock, 1,000 stated value; -0- and 100 shares issued and outstanding at december 31, 2021 and 2020, respectively
preferred stock, .01 par value:
authorized shares – 10,000,000 series b convertible preferred stock, 1,000 stated value; -0- and 100 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively
authorized shares – 600,000,000 issued and outstanding shares – 6,381,541 and 3,834,095 at september 30, 2021 and december 31, 2020, respectively												6,382
authorized shares – 10,000,000
series b convertible preferred stock, 1,000 stated value; -0- and 100 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively
issued and outstanding shares – 6,327,702 and 3,834,095 at june 30, 2021 and december 31, 2020, respectively													6,328
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively														76,095
issued and outstanding shares – 6,315,467 and 3,834,095 at march 31, 2021 and december 31, 2020, respectively														6,315
preferred stock, .01 par value
issued and outstanding shares – 400 and 2,486 march 31, 2020 and december 31, 2019, respectively															376,095
issued and outstanding shares – 13,791,601 and 299,835 at march 31, 2020 and december 31, 2019, respectively															13,792
issued and outstanding shares – 100 and 2,486 september 30, 2020 and december 31, 2019, respectively																76,095
issued and outstanding shares – 3,559,473 and 14,992 at september 30, 2020 and december 31, 2019, respectively																3,559
convertible debentures																	435,711
issued and outstanding shares – 400 and 2,486 june 30, 2020 and december 31, 2019, respectively																	376,095
issued and outstanding shares – 13,834,075 and 299,835 at june 30, 2020 and december 31, 2019, respectively																	13,834
preferred stock, .01 par value (note 7): authorized shares – 10,000,000 issued and outstanding shares – 2,486 and 3,450 at december 31, 2019 and 2018, respectively																		1,932,433
issued and outstanding shares – 3,054 and 3,450 september 30, 2019 and december 31, 2018, respectively																			2,321,823
issued and outstanding shares – 95,627,584 and 437,807 at september 30, 2019 and december 31, 2018, respectively																			95,628
issued and outstanding shares – 3,402 and 3,450 at june 30, 2019 and december 31, 2018, respectively																				2,337,867
issued and outstanding shares – 813,916 and 437,807 at june 30, 2019 and december 31, 2018, respectively																				814
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at march 31, 2019 and december 31, 2018																					76,095
series c convertible preferred stock, 1,000 stated value; -0- and 2,150 shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively
series e convertible preferred stock, 1,000 stated value; -0- and 1,200 shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively
series f convertible preferred stock, 1,000 stated value; 2,583 and -0- shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively																					1,591,763
series g convertible preferred stock, 1,000 stated value; 500 and -0- shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively																					404,250
issued and outstanding shares – 556,489 and 437,807 at march 31, 2019 and december 31, 2018, respectively																					556
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at december 31, 2018 and 2017																						76,095
series c convertible preferred stock, 1,000 stated value; 2,150 and 2,570 shares issued and outstanding at december 31, 2018 and 2017, respectively																						705,238
series d convertible preferred stock, 1,000 stated value; -0- and 1,000 shares issued and outstanding at december 31, 2018 and 2017, respectively
series e convertible preferred stock, 1,000 stated value; 1,200 and -0- shares issued and outstanding at december 31, 2018 and 2017, respectively																						1,190,000
issued and outstanding shares – 218,903,476 and 106,736,810 at december 31, 2018 and 2017, respectively																						218,903
current portion of note payable																							7,294	4,168	1,042
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at september 30, 2018 and december 31, 2017																							76,095
series c convertible preferred stock, 1,000 stated value; 2,570 shares issued and outstanding at september 30, 2018 and december 31, 2017																							842,990
series d convertible preferred stock, 1,000 stated value; -0- and 1,000 shares issued and outstanding at september 30, 2018 and december 31, 2017
series e convertible preferred stock, 1,000 stated value; 1,200 and -0- shares issued and outstanding at september 30, 2018 and december 31, 2017																							1,190,000
issued and outstanding shares – 178,403,476 and 106,736,810 at september 30, 2018 and december 31, 2017																							178,403
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at june 30, 2018 and december 31, 2017																								76,095
series c convertible preferred stock, 1,000 stated value; 2,570 shares issued and outstanding at june 30, 2018 and december 31, 2017																								842,990
series d convertible preferred stock, 1,000 stated value; 205 and 1,000 shares issued and outstanding at june 30, 2018 and december 31, 2017																								200,900
series e convertible preferred stock, 1,000 stated value; 600 and -0- shares issued and outstanding at june 30, 2018 and december 31, 2017																								590,000
issued and outstanding shares – 164,736,810 and 106,736,810 at june 30, 2018 and december 31, 2017																								164,737
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at march 31, 2018 and december 31, 2017																									76,095
series c convertible preferred stock, 1,000 stated value; 2,570 shares issued and outstanding at march 31, 2018 and december 31, 2017																									842,990
series d convertible preferred stock, 1,000 stated value; 550 and 1,000 shares issued and outstanding at march 31, 2018 and december 31, 2017																									539,000
series e convertible preferred stock, 1,000 stated value; 600 and -0- shares issued and outstanding at march 31, 2018 and december 31, 2017																									590,000
authorized shares – 600,000,000 issued and outstanding shares – 141,736,810 and 106,736,810 at march 31, 2018 and december 31, 2017																									141,737
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at december 31, 2017 and 2016, respectively																										76,095
series c convertible preferred stock, 1,000 stated value; 2,570 and 2,868 shares issued and outstanding at december 31, 2017 and 2016, respectively																										842,990
series d convertible preferred stock, 1,000 stated value; 1,000 and -0- shares issued and outstanding at december 31, 2017 and 2016, respectively																										980,000
authorized shares – 600,000,000 and 300,000,000 at december 31, 2017 and 2016, respectively
issued and outstanding shares – 106,736,810 and 55,235,233 at december 31, 2017 and 2016, respectively																										106,737
amounts due to emory university																											22,000
series b convertible preferred stock, 1,000 stated value; 100 shares issued and outstanding at december 31, 2015 and 2014, respectively																											76,095
series c convertible preferred stock, 1,000 stated value; 3,000 and -0- shares issued and outstanding at december 31, 2015 and 2014, respectively																											983,941
authorized shares – 150,000,000 and 75,000,000 at december 31, 2015 and 2014, respectfully
issued and outstanding shares – 31,950,813 at december 31, 2015 and 2014, respectively																											31,951
amounts payable to emory university																												78,917	129,370	677,327	182,980	163,021		156,225
series a convertible preferred stock, 1,000 stated value; -0- and 71 shares issued and outstanding at december 31, 2014 and 2013, respectively
series b convertible preferred stock, 1,000 stated value; 100 and 1,650 shares issued and outstanding at december 31, 2014 and 2013, respectively																												76,095
authorized shares – 75,000,000
issued and outstanding shares – 31,950,813 and 23,765,180 at december 31, 2014 and 2013, respectively																												31,951
property and equipment, net of accumulated depreciation and amortization																													102,486	176,206	248,441	344,202
other assets:
licenses, net of accumulated amortization of 228,856 and 208,933 at december 31, 2012 and 2011 respectively																													20,000
deposits and other assets																													11,010	11,010
total other assets																													31,010	50,933	507,201	90,675	115,560	140,446
preferred stock, .01 par value, 10,000,000 shares authorized; series a convertible preferred stock, 1,000 stated value; 788 and -0- shares issued and outstanding at december 31, 2012 and december 31, 2011, respectively																													312,196
deficit accumulated during the development stage																													-24,767,142	-22,632,002	-20,285,176	-17,537,848	-14,253,596	-10,525,409
licenses, net of accumulated amortization of 208,933 and 184,047 at december 31, 2011 and 2010 respectively																														39,923
deferred offering costs																															430,402
prepaid expenses and other																															48,830	44,615	299,286	49,748
licenses, net of accumulated amortization of 184,047 and 159,161 at december 31, 2010 and 2009 respectively																															64,809
deposits and other																															11,990	980
accounts payable and accrued expenses																															338,628	408,344	176,260	390,993
licenses, net of accumulated amortization of 159,161 and 134,276
at december 31, 2009 and 2008 respectively																																89,695
stock subscriptions receivable																																		897,450
property and equipment, net of accumulated depreciation of 112,795 and 76,667 at december 31, 2008 and 2007, respectively																																	138,847
licenses, net of accumulated amortization of 134,276 and 109,390 at december 31, 2008 and 2007, respectively																																	114,580
amounts payable to related parties																																	170,162
accrued salaries																																		51,320
property and equipment, net of accumulated depreciation of 76,667 and 47,092 at december 31, 2007 and 2006, respectively																																		75,144
licenses, net of accumulated amortization of 109,390 and 84,504 at december 31, 2007 and 2006, respectively																																		139,466

We provide you with 20 years of balance sheets for GeoVax Labs stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GeoVax Labs. Explore the full financial landscape of GeoVax Labs stock with our expertly curated balance sheets.

The information provided in this report about GeoVax Labs stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.